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Hailey±Hailey disease is an autosomal dominant skin
disorder characterized by suprabasal cell separation
(acantholysis) of the epidermis. Mutations in
ATP2C1, the gene encoding a novel, P-type Ca2+-
transport ATPase, were recently found to cause
Hailey±Hailey disease. In this study, we used con-
formation-sensitive gel electrophoresis to screen all
28 translated exons of ATP2C1 in 24 Hailey±Hailey
disease families and three sporadic cases with the dis-
order. We identi®ed 22 different mutations, 18 of
which have not previously been reported, in 25 pro-
bands. The novel mutations comprise three non-
sense, six insertion/deletion, three splice-site, and six
missense mutations and are distributed throughout
the ATP2C1 gene. Six mutations were found in
multiple families investigated here or in our previous
study. Haplotype analysis revealed that two of these
are recurrent mutations that have not been inherited
from a common ancestor. Comparison between
genotype and phenotype in 23 families failed to yield
any clear correlation between the nature of the
mutation and clinical features of Hailey±Hailey
disease. The extensive interfamilial and intrafamilial
phenotypic variability observed suggests that modify-
ing genes and/or environmental factors may greatly
in¯uence the clinical features of this disease. Key
words: Ca2+ transporting ATPase/familial benign chronic
pemphigus/genotype±phenotype correlation/recurrent muta-
tion. J Invest Dermatol 118:338±343, 2002
H
ailey±Hailey disease (HHD, OMIM 16960) is an
autosomal dominantly inherited blistering derma-
tosis. Also known as familial benign chronic
pemphigus, it was ®rst described by the brothers
Hailey in 1939 (Hailey and Hailey, 1939). The
disorder, which usually presents in the third or fourth decade, is
characterized by vesicular lesions, crusted erosions, and warty
papules (Palmer and Perry, 1962; Burge, 1992). These lesions occur
mainly on the neck and intertriginous areas; mucosal involvement
is rare, but has been seen in the mouth, esophagus, and vulva
(Botvinick, 1973; Kahn and Hutchinson, 1974; Evron et al, 1984).
Asymptomatic longitudinal white lines on the ®ngernails are seen in
some patients (Burge, 1992).
Lesions are induced or exacerbated by external factors such as
sweating, friction, and cutaneous infection (Burns et al, 1967;
Leppard et al, 1973; Burge, 1992). Histologically, they show
widespread suprabasal keratinocyte acantholysis with vesicle form-
ation and mild dyskeratosis (Lever and Schaumburg-Lever, 1983).
Ultrastructural studies have revealed breakdown of the desmo-
some±keratin ®lament complexes (Wilgram et al, 1962; Gottlieb
and Lutzner, 1970; Ishibashi et al, 1984).
Although the disease is fully penetrant in adults, it has a
¯uctuating course and expressivity is variable (Burge, 1992). The
milder phenotypes include only subtle nail changes or mild lesions
resembling eczema. In contrast, in severe cases, widespread
malodorous ¯exural lesions can limit physical activity and cause
considerable pain and distress. Due to this wide variation in severity
and range of phenotypes, and the response of some lesions to
corticosteroid and antifungal treatment (Burge, 1992; Misra et al,
1993), misdiagnosis may be common.
There is considerable clinical and histologic overlap with Darier's
disease (DD), a similarly inherited dermatosis (Burge and
Wilkinson, 1992). In HHD, however, acantholysis is generally
more widespread and can be induced by external factors in
clinically uninvolved skin (Burge et al, 1991), whereas dyskeratosis
is a predominant feature of DD (Steffen, 1987). Ikeda et al (1994)
provided de®nitive evidence that these are indeed distinct genetic
entities by demonstrating that HHD was not linked to the DD
locus, mapping instead to chromosome 3q.
Sakuntabhai et al (1999) demonstrated that DD was caused by
mutations in ATP2A2, the gene encoding the sarco-endoplasmic
reticulum Ca2+ ATPase SERCA2. This was followed by the
identi®cation of ATP2C1, encoding a novel Ca2+ pump, as the
HHD disease gene (Hu et al, 2000; Sudbrak et al, 2000). Studies of
PMR1, the yeast homolog of ATP2C1, have shown that it is
localized to the Golgi (Rudolph et al, 1989; Antebi and Fink,
1992). Recent investigation of the Caenorhabditis elegans homolog
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provided evidence that this class of Ca2+ ATPases is capable of
transporting Ca2+ from the cytosol into this compartment (Van
Baelen et al, 2001); the Golgi itself is known to function as an
inositol 1,4,5-trisphosphate-sensitive Ca2+ store (Pinton et al,
1998). Hu et al (2000) showed that regulation of cytosolic Ca2+
was impaired in cultured keratinocytes from lesions and clinically
uninvolved skin of HHD patients. These discoveries suggest that
intracellular Ca2+ stores play a major role in regulation of epidermal
cell±cell adhesion and differentiation. Previous studies had shown
that an increase in extracellular Ca2+ can induce desmosome and
adherens junction assembly and keratinocyte strati®cation (Watt
et al, 1984; O'Keefe et al, 1987).
The majority of ATP2C1 mutations thus far reported predict loss
of function of the pump (Hu et al, 2000; Sudbrak et al, 2000),
suggesting a haploinsuf®ciency mechanism for dominant inherit-
ance. The precise mechanism by which defects in the Ca2+ pump
lead to the HHD phenotype, however, is not yet clear. In order to
provide more information about the functional signi®cance of
ATP2C1 mutations, we conducted a large-scale screening of 24
HHD families and three sporadic cases. We report 18 novel
mutations in ATP2C1, and discuss the relationship between
genotype and phenotype in 64 HHD patients.
MATERIALS AND METHODS
Patients Twenty-four families and three sporadic patients were
included in this study. Two families came from Sri Lanka (SL pre®x,
Table I), one came from France (FR5), and one sporadic case was of
Indian origin (OX23); the remainder were British. Diagnosis of HHD in
each case was made by a dermatologist based on clinical and
histopathologic ®ndings. Peripheral blood or buccal swabs were collected
for DNA isolation after patients had given informed consent. For 14
families from this study and nine from our previous study (Sudbrak et al,
2000) the following HHD parameters were assessed: age of onset,
precipitating factors, progression, sites of outbreak, history of secondary
infection, and speed of lesion development following induction. Extent
and responsiveness to treatment and other medical problems were also
documented. Disease severity was classi®ed based on the extent of
outbreaks and number of affected areas. Referral and admission to
hospital were also considered as criteria for disease severity. A patient was
considered to have mild disease if they had a history of HHD at one site
only. History of HHD at two to ®ve sites or referral to hospital was
classi®ed as moderate disease, whereas more extensive manifestation at
greater than ®ve sites or admission to hospital was classed as severe.
Mutation analysis Genomic DNA was extracted from peripheral
blood using the Nucleon kit (Scotlab, Lanarkshire, U.K.) or from buccal
swabs, using methods described previously (Philippe et al, 1997). All 28
translated exons (including exon 1 reported by Hu et al, 2000) plus
¯anking splice sites were ampli®ed from the proband DNA (primer
sequences available on request). Polymerase chain reactions (PCRs) were
carried out with standard reaction mixes containing 2.5 mM MgCl2.
After an initial denaturation step at 94°C for 15 min, 35 cycles of
ampli®cation consisting of 30 s at 94°C, 30 s at 58°C, and 30 s at 72°C
were performed. Ampli®cation products were run on 3% agarose gels for
detection of large insertions/deletions prior to mutation screening by
conformation-sensitive gel electrophoresis (CSGE), as described by
Ganguly et al (1993). PCR products showing aberrant electrophoretic
mobility or extra bands were puri®ed using a QIAquick PCR
puri®cation kit (Qiagen, Surrey, U.K.). These were then sequenced in
both directions by means of the BigDye Terminator Cycle Sequencing
Ready Reaction kit (PE-Applied Biosystems, Cheshire, U.K.) and were
run on an ABI PRISM 377 DNA Sequencer (PE-Applied Biosystems).
The presence of each mutation was veri®ed in the proband and any
available family members by restriction digestion or sequencing.
Haplotype analysis Haplotyping was performed by PCR ampli®c-
ation of genomic DNA from patients and other family members using
¯uorescently labeled primers speci®c for the polymorphic microsatellite
markers D3S3514, D3S1596, D3S1587, and D3S1292. Products were
denatured with formamide buffer and GS500 ROX size standard (PE-
Applied Biosystems), loaded onto a 6% acrylamide gel, and subjected to
electrophoresis on an ABI PRISM 373 A DNA Sequencer. Samples
were aligned and analyzed using the GeneScan Fragment Analysis and
Genotyper programs (PE-Applied Biosystems).
RESULTS
The entire coding and ¯anking intronic sequence of ATP2C1 was
screened for mutations by CSGE in 24 HHD families and three
sporadic cases with HHD. PCR products with aberrant electro-
phoretic mobility were seen in 21 probands. Sequencing revealed
14 different mutations. Six probands in which no abnormal CSGE
bands were detected were sequenced in all coding exons and
¯anking intronic regions, revealing a further four mutations
(Table I, Fig 1). All available family members were screened for
the relevant mutation using the veri®cation method outlined in
Table I; in each case, the mutation cosegregated consistently with
the affection status. We failed to ®nd any disease mutation in two
HHD families despite CSGE and sequencing analysis of all coding
exons of ATP2C1.
Nonsense mutations Four different base substitutions that result
in premature termination codons (PTCs) were identi®ed
(Table I). Family OX19 has a C®T transition at CAA
glutamine codon 249, resulting in substitution of a TAA stop
codon. Family SL3 has a C®G transversion at TCA serine codon
562, and families NC5, NC6, and OX20 have a C®T transition at
CGA arginine codon 806; both these substitutions lead to a TGA
stop codon. Family OX12 has a C®T transition at CAG glutamine
codon 606, leading to a TAG stop codon.
Insertion/deletion mutations Seven different insertions or
deletions were identi®ed. Each leads to a shift in the reading
frame, introducing a PTC (Table I). Families OX10, OX21, and
OX11 and patient NC10 have 1 bp deletions (490delT, 1045delT,
1723delG, 1001delA). These result in a PTC 24, 6, 24, and 12
codons, respectively, downstream of the deletion site. Family NC3
has a 1 bp insertion, 519insA, which results in a PTC 3 codons
downstream. Four basepair deletions were found in two families:
1089delTCAC in family OX22; and 2374delTTTG in family FR5.
These deletions are the cause of a PTC 21 and 9 codons,
respectively, downstream.
Splice-site mutations Four different mutations are predicted to
result in altered mRNA splicing (Table I). Families NC7 and
OX15 have a G®A transition at the invariant splice acceptor site
consensus sequence AG of introns 8 and 15, respectively. This G at
the splice acceptor site of intron 26 is deleted in family SL4.
Families OX13 and OX16 both have an A®T transversion at
position +3 of the splice donor consensus sequence GTPuAGT.
Unfortunately, as RNA was not available from these families, it was
not possible to explore the effect of these mutations on splicing.
Missense mutations Seven different base changes resulting in an
amino acid substitution were identi®ed (Table I). None of these
missense mutations was found when screening 50 normal
individuals using the veri®cation methods outlined in Table I.
All but one of these mutations occurred at amino acid positions that
are very highly conserved or invariant between ATP2C1 paralogs
(ATP2B1-4, ATP2A1-3) and orthologs (in rat, fruit ¯y, nematode,
yeast, archaebacteria, and eubacteria). The substitutions occur
throughout the predicted secondary structure of ATP2C1 (Fig 1).
Mutation P201L occurs in the predicted actuator domain of
ATP2C1. Three mutations (G309C, D742Y, and G789R) are
amino acid substitutions in predicted transmembrane regions M4,
M6, and M7, respectively. Mutation L341P occurs in the region
linking stalk domain 4 and the phosphorylation domain. Mutation
C411R occurs in the phosphorylation domain itself, whereas
mutation I580V is located in the ATP-binding domain. The latter
mutation is the only conservative amino acid change associated
with HHD identi®ed in this study: isoleucine differs from valine
only by an additional methyl group. This amino acid is invariant in
all Ca2+ ATPases analyzed, however, suggesting that it may play a
precise structural role.
Haplotype analysis Several mutations were found in two or
more families within this study, or had been identi®ed in another
family in a previous study in this laboratory. Families SL3, SL4, and
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OX14 have mutations (S562X, 2630±1delG, and P201L) that had
been previously identi®ed in SL1, SL2, and OX3, respectively
(Sudbrak et al, 2000). Families NC5, NC6, and OX20 in this study
share the same mutation (R806X), as do families OX13 and OX16
(832 + 3A®T). The mutation 2374delTTTG has been reported
twice elsewhere (family OX7 in Sudbrak et al, 2000; families
HHD-Du and HHD-Ho in Hu et al, 2000). In order to distinguish
between founder mutations and those that had arisen more than
once independently, haplotype analysis was performed by use of
polymorphic microsatellite markers close to the ATP2C1 gene. In
all but two cases, families with the same mutation shared the same
disease haplotype and were therefore deemed to be related; this was
consistent with the shared geographic origin of the relevant
families. For mutation R806X, it was not possible to say whether
families NC5 and OX20 were related, as they shared the most
common haplotype, present also in some unaffected spouses.
Figure 1. Localisation of ATP2C1 mutations
identi®ed in this and previous studies. The
putative protein domains of ATP2C1, based on
comparison with ATP2A1 (SERCA1) secondary
structure, are illustrated. Polypeptide loops
connecting domains are shaded. Novel mutations
are depicted above the schematic; those previously
reported (in Hu et al, 2000 and Sudbrak et al,
2000) are shown below. The number of pedigrees
in which identical mutations were identi®ed is
shown in parentheses; this number is underlined
where haplotyping analysis indicated families that
were not related.
Table I. ATP2C1 mutations in HHD patients
Patients Inheritance DNA changea Protein changea Location Putative protein domainb Veri®cation method
Nonsense
OX19 Familial C745T Q249X Exon 9 S3 sequencing
SL3 Familial C1685G S562X Exon 18 ATP-binding BseRI
OX12 Familial C1816T Q606X Exon 19 ATP-binding ± hinge sequencing
NC5 Familial C2416T R806X Exon 25 M8 AvaI, XhoI
NC6 Familial C2416T R806X Exon 25 M8 AvaI, XhoI
OX20 Familial C2416T R806X Exon 25 M8 AvaI, XhoI
Frameshift
OX10 Familial 490delT 163LfsX24c Exon 7 Actuator sequencing
NC3 Familial 519insA 173LfsX3 Exon 7 Actuator sequencing
NC10 Sporadic 1001delA 333KfsX12 Exon 12 S4 ± phosphorylation sequencing
OX21 Familial 1045delT 348CfsX6 Exon 13 Phosphorylation sequencing
OX22 Familial 1089delTCAC 363TfsX21 Exon 13 Phosphorylation sequencing
OX11 Familial 1723delG 574QfsX24 Exon 18 ATP-binding AlwNI
FR5 Familial 2374delTTTG 791LfsX9 Exon 24 M7 TthIII1
Splice site
NC7 Familial 688±1G®A (aberrant splicing) Intron 8 Actuator A¯I
OX13 Familial 832 + 3 A®T (aberrant splicing) Intron 10 M3 sequencing
OX16 Familial 832 + 3 A®T (aberrant splicing) Intron 10 M3 sequencing
OX15 Familial 1309±1G®A (aberrant splicing) Intron 15 Phosphorylation sequencing
SL4 Familial 2630±1delG (aberrant splicing) Intron 26 M10 XhoII, BglII
Missense
OX14 Familial C602T P201L Exon 8 Actuator EarI, BseRI
OX24 Sporadic G925T G309C Exon 12 M4 BsaI
OX8 Familial T1022C L341P Exon 12 S4 ± phosphorylation sequencing
NC8 Familial T1231C C411R Exon 15 Phosphorylation FspI
NC9 Familial A1738G I580V Exon 18 ATP-binding sequencing
OX18 Familial G2224T D742Y Exon 23 M6 sequencing
OX23 Sporadic G2365A G789R Exon 24 M7 sequencing
aNucleotides and amino acids are numbered according to the cDNA sequence of ATP2C1 isoform as reported by Hu et al (2000), with the adenosine of the initiation
codon assigned position 1.
bPutative protein domain prediction is based on the position of the equivalent residue within the structure of ATP2A1 (SERCA1).
c163LfsX24 indicates a frameshift with leucine 163 as the ®rst affected amino acid and a PTC introduced 24 codons downstream.
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Family NC6 displayed a different disease haplotype, however,
implying that this family is unrelated to the other two. The
haplotypes associated with the mutation 2374delTTTG in families
FR5 and OX7 were also different, suggesting that these families are
unrelated as well.
Genotype±phenotype comparison To determine whether the
nature and position of mutations in ATP2C1 are related to any
particular aspects of HHD phenotype, we attempted to correlate
our molecular data with any available information on patient
phenotype (Table II). Investigated here are nine cases previously
described (Sudbrak et al, 2000), in addition to 14 cases from this
study, all of which are familial. The study included clinical data
from a total of 64 patients, all of British origin.
Age of onset was mainly distributed between 11 and 40 y.
Symptoms began to manifest between 21 and 30 y in 47% of cases
studied. 18% of patient symptoms manifested between 11 and 20 y
and 18% between 31 and 40 y. The age of onset was 41±50 y for
12% of patients. One patient started with the disease before 10 y of
age, whereas in two cases blistering only appeared at over 50 y. All
patients demonstrated some classical ¯exural disease, which
irritated, often became malodorous, and, in some cases, limited
their mobility. Painful erosions, vesicopustules, and scaly erythe-
matous plaques, which are typical of the disease, commonly erupted
primarily at the neck, groin, and axillae. Other frequently affected
areas included the chest, shoulders, back, and beneath the breasts;
less common sites included the umbilicus, arms, genitalia, scalp,
waist, buttock, ear, leg, and face. Lesion-precipitating factors
included heat and resultant sweating, friction, and stress. The time
taken for lesions to develop from these triggers ranged from
minutes to 3 d, but was most commonly within 24 h.
The clinical features in 36 of these patients (all those with OX
pre®xes, Table II) have been described in a previous study (Burge,
1992). Bacterial skin infections had occurred in 11 of 36 (31%) of
these patients. Viral infections were noted in affected areas in three
of 36 (8%) of patients. Corticosteroids and antibiotics had been
prescribed for 31 of 36 (86%) and 14 of 36 (39%) of the patients,
respectively. Corticosteroid treatment was deemed useful in 28 of
31 (90%) of cases; antibiotics were considered helpful in 11 of 14
(79%) of cases. No other medical conditions were associated with
the disease.
Mutations were classi®ed into three groups based on the predicted
effect on ATP2C1 (Table II). Extensive interfamilial and intra-
familial variation was noted in clinical features such as age of onset,
sites of outbreak, severity, and progression of the disease. Group 1
consists of 14 families with 12 distinct mutations leading to PTCs,
predicted to cause haploinsuf®ciency of ATP2C1 through non-
sense-mediated mRNA decay. Patients from NC5, NC6, and
OX20 share the same nonsense mutation (R806X). Severe and
moderate symptoms were noted in NC5 and NC6; OX20 members
showed moderate disease. Symptoms deteriorated with age in one
patient and improved in another in NC5 and OX20. In NC6 the
disease deteriorated in one patient and remained static in the rest.
The second group consists of two families, each with distinct
mutations at exon boundaries, likely to lead to abnormal splicing.
Both patients studied had severe disease. In one the symptoms
worsened, whereas in the other they were static. The third group
comprises seven families, with ®ve distinct mutations resulting in
nonconservative amino acid substitutions. Families OX3 and
OX14, and OX1 and OX2, share the same mutations (P201L
and T570I, respectively). Patients in OX3 had moderate or severe
disease, with improving, static, or deteriorating progression.
Moderate disease improved over time in OX14. For OX1,
moderate and mild phenotypes that were static or improving
were observed, whereas disease in OX2 members fell into all three
severity classes with static or deteriorating progression.
Table II. Genotype±phenotype comparison in patients with a de®ned disease phenotype
Patients Putative protein domain Age of onsetb Severityc Progressiond
Group 1. Nonsense or insertion/deletion mutation (n = 36)
NC2 (7) Upstream stalk c (5), d (2) Sv (3), Md (2), Mi (2) S (2), I (3), D (2)
OX5 (1) Upstream stalk c (1) Sv (1) S (1)
OX10 (1) Actuator f (1) Md (1) ND (1)
NC3 (2) Actuator d (1), e (1) Md (1), Mi (1) S (1), I (1)
OX19 (1) S3 c (1) Mi (1) S (1)
OX22 (1) Phosphorylation c (1) Md (1) I (1)
NC1 (11) Phosphorylation a (1), c (3), e(3), f (1), nd (3) Sv (1), Md (4), Mi (6) S (3), I (1), D (5), ND (2)
OX11 (1) ATP-binding e (1) Md (1) ND (1)
OX12 (1) ATP-binding ± hinge c (1) Sv (1) D (1)
OX7 (1) M7 b (1) Sv (1) S (1)
NC5 (2) M8 b (1), c (1) Sv (1), Md (1) I (1), D (1)
NC6 (3) M8 b (1), c (1), d (1) Sv (2), Md (1) S (2), D (1)
OX20 (2) M8 c (2) Md (2) I (1) D (1)
OX4 (2) M9 ± M10 b (2) Sv (1), Md (1) S (2)
Group 2. Splice-site mutation (n = 2)
NC7 (1) Actuator c (1) Sv (1) S (1)
OX13 (1) M3 d (1) Sv (1) D (1)
Group 3. Missense mutation (n = 26)
OX3 (4) Actuator c (3), e (1) Sv (2), Md (2) S (1), I (2), D (1)
OX14 (1) Actuator d (1) Mi (1) I (1)
OX8 (9) S4 ± phosphorylation b (4), c (2), d (2), e (1) Sv (4), Md (4), Mi (1) S (4), I (2), D (2), ND (1)
NC8 (2) Phosphorylation c (1), d (1) Sv (1), Md (1) I (1), D (1)
OX1 (3) ATP-binding b (1), c (2) Md (2), Mi (1) S (2), I (1)
OX2 (6) ATP-binding b (1), c (3), d (1), nd (1) Sv (2), Md (1), Mi (3) S (3), D (2), ND (1)
OX18 (1) M6 d (1) Md (1) S (1)
an, number of affected individual(s) in each family for whom clinical data were available. Adjacent families sharing a common mutation are italicized.
bAge of onset, a, < 10 y; b, 10±20 y; c, 21±30 y; d, 31±40 y; e, 41±50 y; f, > 50 y of age; nd, no data.
cSeverity, Sv, severe; Md, moderate; Mi, mild.
dDisease progression: S, static; I, improving; D, deteriorating; ND, no data.
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DISCUSSION
From 27 patients screened, we found 22 different mutations likely
to cause HHD in 25 probands. Eighteen of these disease mutations
have not previously been reported, indicating substantial allelic
heterogeneity with no single mutation causing the majority of
HHD cases in the population. No disease mutations in ATP2C1
were detected in two families in this study with typical HHD. As
there is no evidence for locus heterogeneity, it is possible that there
are mutations located within the 5¢ or 3¢ untranslated regions, in the
promoter or extragenic regulatory elements, or within intronic
sequences not screened in this study. Small deletions and
rearrangements preventing ampli®cation of one allele will also
not be detected with this methodology. The mutations identi®ed in
this study are scattered throughout the ATP2C1 gene, indicating
no ``hotspots'' or clustering of mutations. Of the missense
mutations, one is present in the actuator domain, one in each of
the M4, M6, and M7 transmembrane domains, one in stalk sector
S4, one in the phosphorylation site, and one in the ATP-binding
domain (Fig 1).
Mechanism of recurrent ATP2C1 mutations Six mutations
in this investigation had been discovered in our previous study, or
were present in multiple seemingly unrelated families within this
cohort. Haplotype analysis suggested that most of these instances
were caused by inheritance of the same mutation in a common
ancestor. Of the three families carrying the R806X (C2416T)
mutation, results as to the relationship between NC5 and OX20
were inconclusive. The disease haplotype for family NC6 was
clearly different, however, implying that this mutation has arisen
independently at least twice. It is not surprising that this is a
recurrent mutation, as the cytosine involved is part of a CG
dinucleotide and as such is especially vulnerable to methylation and
spontaneous deamination to thymine. The two families (FR5 and
OX7) sharing the 2374delTTTG mutation seem to be unrelated;
Hu et al (2000) report that the two families sharing this mutation in
their study are also unrelated. As the mutation occurs within the
tandem repeat TTTGTTTG, it is plausible that this mutation has
arisen multiple times through replication slippage. Interestingly, a
deletion of the tetranucleotide TTGT 1 bp downstream of this
mutation has also been reported (Hu et al, 2000, and Fig 1),
suggesting that this region is particularly susceptible to slipped
strand mispairing.
Predicted effects of ATP2C1 mutations on function Eleven
of 22 (50%) of the ATP2C1 lesions identi®ed in this study are
nonsense or insertion/deletion mutations that lead to PTCs and
therefore predict absence or marked reduction of mutated ATP2C1
via nonsense-mediated mRNA decay. This brings further support
to the theory that haploinsuf®ciency of ATP2C1 is a prevalent
mechanism for the dominant inheritance of HHD. The possibility
that some PTC mutations leading to truncated proteins and some
missense mutations might cause HHD through a dominant
negative mechanism cannot be discounted, however.
In the absence of RNA from affected patients, it is dif®cult to
predict what effect the four splice-site mutations identi®ed in this
study have at the transcript level. In the case of the splice acceptor
mutation in intron 26 (Table I), however, it seems likely that
normal splicing of exon 27 is impaired, and that 3¢ splicing isoforms
A and B (isoform a in Sudbrak et al, 2000, and Hu et al, 2000;
isoform b in Sudbrak et al, 2000, respectively), which contain this
exon, cannot be produced from the mutant allele. Given that
patients with this mutation display classical HHD, the implication is
that at least the 5¢ part of exon 27 is essential for some functions of
ATP2C1, and that the alternative splicing isoform C (isoform b in
Hu et al, 2000), which lacks this exon, cannot compensate for it.
Seven of 22 (32%) of ATP2C1 mutations identi®ed in this study
are missense mutations. These were all found to segregate with the
disease phenotype within the relevant family, and were not
detected in 100 control chromosomes, which suggests that they
do not represent benign polymorphisms. Three mutations occurred
at amino acid residues conserved between ATP2C1 and the
SERCA1 pump that have been investigated in the latter by means
of site-directed mutagenesis. Substitution of residues Asp-800 and
Gly-310 in SERCA1 (equivalent to the positions involved in the
ATP2C1 mutations D742Y and G309C, respectively) have both
been shown to abrogate protein function (Clarke et al, 1989a, b;
Andersen and Vilsen, 1992; Andersen et al, 1992; Vilsen and
Andersen, 1992). Asp-800 is believed to provide an oxygen ligand
for Ca2+ in the ATPase (Clarke et al, 1989a); hence substitution of
this residue for a nonoxygen-containing side chain will severely
compromise Ca2+ binding in the D742Y mutant. We hypothesize
that steric obstruction of the immediately adjacent Ca2+ binding
Asp side chain is responsible for ATP2C1 malfunction in the
G309C mutant, as SERCA1 Ca2+ af®nity decreases as the size of
the substituted side chain in this position is increased (Andersen et al,
1992). The latter mutation occurs at a site in ATP2C1 corres-
ponding to one in ATP2A2 (G310V) that is mutated in a patient
with classical DD (patient 13 in Jacobsen et al, 1999); clearly this
residue is crucial for Ca2+ ATPase function within the context of
epidermal disease. The proline residue equivalent to that of
ATP2C1 mutation P201L was changed to an alanine residue in
SERCA1 without discernible loss of Ca2+ af®nity or transport
(Vilsen et al, 1989). Investigations in ATP2C1 are required to see
whether this residue plays a role critical only in this protein.
Of the other missense mutations, two (L341P and I580V) occur
at residues that are invariant across ATP2C1 orthologs and paralogs;
one (C411R) is invariant in all homologs except plasma membrane
ATPases; and one (G789R) occurs at a position that is occupied by
a neutral, nonpolar amino acid in all homologs. This high degree of
conservation suggests that the residues involved are essential for
ATP2C1 function: mutagenesis of these residues and functional
analysis of the mutants is required to elucidate exactly what role
they play in the protein.
Although mutations in ATP2C1 have been established as the
cause of HHD (Hu et al, 2000; Sudbrak et al, 2000), it is not clear
how the disruption of ATP2C1 function results in the epidermal
defects seen in the skin lesions. Yeast PMR1 null mutants are found
to grow poorly on low-Ca2+ media and are defective in protein
secretion and glycosylation (Rudolph et al, 1989; Antebi and Fink,
1992). This raises the possibility that a decrease in Ca2+ concen-
tration in the Golgi caused by haploinsuf®ciency of ATP2C1 could
lead to a decrease in glycosylation and/or missorting of cell±cell
adhesion molecules, such as desmosomal proteins. This may cause
an inability to maintain structurally intact desmosomes, leading to
the acantholysis characteristic of HHD. Alternatively, the defect
could be caused by an increase in cytosolic Ca2+, leading to changes
in, for example, gene expression or post-translational protein
modi®cation. It has been suggested that desmosomal glycoproteins
differ in the extent of glycosylation between different cell types
(Suhrbier and Garrod, 1986). Therefore, the reason clinical
symptoms of HHD are restricted to the epidermis despite
expression of ATP2C1 in several tissues (Hu et al, 2000) could
be that the particular glycosylation state of the desmosomal
glycoproteins in this cell type leaves them vulnerable to subtle
Ca2+ changes caused by haploinsuf®ciency of ATP2C1.
Alternatively, there may be various compensatory mechanisms
operating in noncutaneous tissues, which are absent in the skin.
The related fact that certain regions of the epidermis seem more
prone to acantholysis despite similar levels of ATP2C1 expression
(Hu et al, 2000), and that lesions can be induced in clinically normal
skin (Burge et al, 1991), could be explained by a partial overlap of
function of ATP2C1 and other Ca2+ pumps. Congruent with this
view are studies showing that thapsigargin, a SERCA-pump-
speci®c inhibitor, depletes Ca2+ stores in the Golgi to some extent
(Pinton et al, 1998). Furthermore, although Ca2+ homeostasis is
regulated in the absence of any obvious SERCA-type pumps in
yeast, rabbit SERCA1 can rescue lethality of yeast mutants lacking
endogenous Ca2+ transporters (Degand et al, 1999). In general,
haploinsuf®ciency of ATP2C1 could be compensated by other
Ca2+ regulatory mechanisms in the cell, but when the cell is placed
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under stress, e.g., mechanical from friction, or heat-induced, the
subtle de®ciency is exposed.
Genotype±phenotype correlations No clear genotype±
phenotype correlation was observed in the group of patients for
whom clinical information was available. Neither age of onset,
pattern of outbreak, severity, nor progression of disease could be
attributed to mutation type or location in the putative protein
structure. Such extensive phenotypic variation suggests that
modifying genes and/or environmental factors greatly in¯uence
clinical features of the disease. Hypothetical environmental factors
exposed during this study as possibly in¯uencing disease severity
include excessive weight and occupational activity that could
induce friction in an HHD sufferer. More detailed clinical
information encompassing a larger group of patients could be
important in uncovering correlations between molecular and
clinical aspects of HHD.
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